Monte Rosa Therapeutics, Inc. GLUE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$130.01M— | -$38.63M— | —— | —— | —— | ||
| $8.34M+0.8% | $8.36M+2.9% | $8.33M+5.4% | $8.34M+9.2% | $8.27M+18.7% | ||
| $19.52M+5.2% | $18.87M+4.1% | $19.03M+7.3% | $18.94M+5.7% | $18.55M+5.6% | ||
| -$14.68M-142% | -$22.8M-154% | $149.14M— | $27.72M— | $34.67M— | ||
| $4.98M+18.8% | $4.7M+17.9% | $4.12M-25.1% | $3.86M-42.8% | $4.19M-62.7% | ||
| —— | —— | —— | —— | —— | ||
| $358.67M+264% | $30.35M-69.3% | $1.34M-98.9% | $1M-99.2% | $98.66M+256% | ||
| —— | —— | —— | —— | —— | ||
| -$19.66M-164% | -$27.5M-172% | $145.02M— | $23.85M— | $30.48M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Monte Rosa Therapeutics, Inc. generate?
- Monte Rosa Therapeutics, Inc. (GLUE) generated -$14.7M in operating cash flow over the trailing twelve months.
- What is Monte Rosa Therapeutics, Inc.'s free cash flow?
- After $5.0M of capital expenditures, Monte Rosa Therapeutics, Inc.'s free cash flow was -$19.7M over the trailing twelve months, down 164.5% year over year.
- Where does Monte Rosa Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
